Company profile: Vor Bio
1.1 - Company Overview
Company description
- Provider of immuno-oncology therapies for AML, including VOR33, a gene-edited hematopoietic stem cell therapy lacking CD33 to shield healthy blood cells from targeted therapies, and VCAR33ALLO, an allogeneic anti-CD33 CAR-T for relapsed or refractory post-transplant AML. Runs clinical trials (VBP101, VBP301) and collaborates with blood cancer advocacy groups to support the AML patient community.
Products and services
- Clinical Trials for AML: Clinical-stage studies, including VBP101 and VBP301, actively evaluating safety and efficacy of Vor Biopharma’s therapies in AML treatment
- VCAR33ALLO: An allogeneic CAR-T cell therapy targeting CD33, derived from healthy donors, intended for relapsed or refractory AML post-transplant, delivering CD33-directed activity against disease
- VOR33: A custom-engineered gene-edited hematopoietic stem cell therapy lacking CD33 protein, shielding healthy blood cells from targeted therapies by eliminating CD33 expression and enabling selective protection during treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vor Bio
Neogene Therapeutics
HQ: The Netherlands
Website
- Description: Provider of T cell therapies targeting cancer neo-antigens, developing technologies to engineer designer T cells with optimized neo-antigen specificities to seek and destroy cancer cells. Offers engineered TCR therapies for solid tumors, including a TP53 R175H-targeting TCR therapy currently in Phase I trials in the US.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neogene Therapeutics company profile →
NBE Therapeutics
HQ: Switzerland
Website
- Description: Provider of oncology therapies based on proprietary antibody-drug conjugates, including SMAC-Technology enzymatic conjugation for site-specific ADC manufacturing, Transpo-mAb mammalian cell display antibody discovery, a PNU-159682 anthracycline toxin payload platform, immune-oncology ADCs that activate CD8 cytotoxic T cells, and the ROR1-targeting NBE-002 candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NBE Therapeutics company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
Quantum Surgical
HQ: France
Website
- Description: Provider of robotic-assisted interventional oncology solutions for minimally invasive liver cancer treatment, including Epione for planning, targeting, delivery and confirmation of tumor ablation; CT/MRI fusion-based multimodal planning; real-time respiratory monitoring; post-ablation margin verification; and robotic guidance with navigation and haptics (6 DOF) for precise targeting and safe needle release.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantum Surgical company profile →
X4 Pharmaceuticals
HQ: United States
Website
- Description: Provider of oral small molecule CXCR4 antagonists, including mavorixafor to mobilize white blood cells and improve immune function in patients with WHIM syndrome and certain chronic neutropenic disorders; runs a global Phase 3 WHIM trial with positive results and awaiting FDA approval, plus a Phase 2 trial in chronic neutropenic disorders with plans for Phase 3.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full X4 Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vor Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vor Bio
2.2 - Growth funds investing in similar companies to Vor Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vor Bio
4.2 - Public trading comparable groups for Vor Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →